Naiyer Rizvi

Naiyer Rizvi published the foundational study demonstrating that tumor mutational burden and neoantigen load predict response to pembrolizumab in NSCLC, establishing the scientific basis for TMB as an immunotherapy biomarker. His subsequent investigations have refined the utility of TMB across tumor types, contributed to the KEYNOTE-158 pan-tumor TMB analysis, and examined clonal versus subclonal neoantigens as predictors of IO durability. He leads thoracic and immuno-oncology research at Columbia University and has been influential in driving regulatory consideration of TMB as a companion diagnostic. Rizvi's work underpins the pan-tumor pembrolizumab approval for TMB-high cancers.